KR20230066040A - 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 - Google Patents
만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 Download PDFInfo
- Publication number
- KR20230066040A KR20230066040A KR1020237011629A KR20237011629A KR20230066040A KR 20230066040 A KR20230066040 A KR 20230066040A KR 1020237011629 A KR1020237011629 A KR 1020237011629A KR 20237011629 A KR20237011629 A KR 20237011629A KR 20230066040 A KR20230066040 A KR 20230066040A
- Authority
- KR
- South Korea
- Prior art keywords
- administered
- dose
- ser
- bispecific antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076733P | 2020-09-10 | 2020-09-10 | |
| US63/076,733 | 2020-09-10 | ||
| PCT/EP2021/075015 WO2022053653A1 (en) | 2020-09-10 | 2021-09-10 | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230066040A true KR20230066040A (ko) | 2023-05-12 |
Family
ID=77924347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237011629A Pending KR20230066040A (ko) | 2020-09-10 | 2021-09-10 | 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230312757A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210746A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023541858A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066040A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116437956A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021342342A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004327A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190349A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301096A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002546A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053653A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102813816B1 (ko) * | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| JP2023542290A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー/エス | 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| WO2022053657A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| IL301086A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| IL319999A (en) * | 2022-11-02 | 2025-06-01 | Genmab As | Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome |
| GB202217993D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Therapeutic antibodies |
| WO2024236031A1 (en) | 2023-05-15 | 2024-11-21 | Genmab A/S | Highly purified epcoritamab compositions |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| CA2531118C (en) | 2003-07-01 | 2013-01-08 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| KR101540823B1 (ko) | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| WO2008145141A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| AU2010229705A1 (en) | 2009-03-27 | 2011-10-20 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| WO2012023053A2 (en) | 2010-08-16 | 2012-02-23 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| CN104936985A (zh) | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| BR112016000666A2 (pt) | 2013-07-12 | 2017-10-03 | Zymeworks Inc | Constructos de ligação de antígeno cd3 e cd19 biespecíficos |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| WO2015121318A1 (en) | 2014-02-12 | 2015-08-20 | Sanofi | Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| US20160199399A1 (en) | 2015-01-09 | 2016-07-14 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness in cancer patients |
| CN104922688A (zh) | 2015-02-10 | 2015-09-23 | 昆明贵研药业有限公司 | 奥沙利铂的环糊精复合物及制备方法 |
| FI3322727T3 (fi) | 2015-07-15 | 2026-03-17 | Genmab As | Humanisoituja tai kimeerisiä CD3-vasta-aineita |
| WO2017210485A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| EP3541843A1 (en) * | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| AU2018259078B2 (en) | 2017-04-27 | 2021-10-07 | Astrazeneca Ab | C5-anilinoquinazoline compounds and their use in treating cancer |
| BR112020015052A2 (pt) | 2018-02-09 | 2020-12-08 | Genmab A/S | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes |
| EP4427810A3 (en) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| AU2020328195A1 (en) | 2019-08-15 | 2022-03-03 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses |
| KR20230008775A (ko) | 2020-05-08 | 2023-01-16 | 젠맵 에이/에스 | Cd3 및 cd20에 대한 이중특이적 항체 |
| BR112023004319A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma difuso de grandes células b |
| IL301086A (en) | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| WO2022053657A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| JP2023542290A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー/エス | 濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 |
-
2021
- 2021-09-10 CN CN202180069957.XA patent/CN116437956A/zh active Pending
- 2021-09-10 EP EP21777973.5A patent/EP4210746A1/en active Pending
- 2021-09-10 AU AU2021342342A patent/AU2021342342A1/en active Pending
- 2021-09-10 WO PCT/EP2021/075015 patent/WO2022053653A1/en not_active Ceased
- 2021-09-10 JP JP2023515672A patent/JP2023541858A/ja active Pending
- 2021-09-10 MX MX2023002546A patent/MX2023002546A/es unknown
- 2021-09-10 CA CA3190349A patent/CA3190349A1/en active Pending
- 2021-09-10 KR KR1020237011629A patent/KR20230066040A/ko active Pending
- 2021-09-10 IL IL301096A patent/IL301096A/en unknown
- 2021-09-10 US US18/025,202 patent/US20230312757A1/en active Pending
- 2021-09-10 BR BR112023004327A patent/BR112023004327A2/pt unknown
- 2021-12-22 US US17/559,935 patent/US11858995B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023004327A2 (pt) | 2023-04-04 |
| CA3190349A1 (en) | 2022-03-17 |
| IL301096A (en) | 2023-05-01 |
| EP4210746A1 (en) | 2023-07-19 |
| JP2023541858A (ja) | 2023-10-04 |
| AU2021342342A1 (en) | 2023-04-13 |
| US20220112287A1 (en) | 2022-04-14 |
| US20230312757A1 (en) | 2023-10-05 |
| US11858995B2 (en) | 2024-01-02 |
| MX2023002546A (es) | 2023-03-14 |
| WO2022053653A1 (en) | 2022-03-17 |
| CN116437956A (zh) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11608383B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | |
| US11535679B2 (en) | Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma | |
| US11858995B2 (en) | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia | |
| KR20230066583A (ko) | 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 | |
| US20230312759A1 (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
| US20230355753A1 (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
| US20240174761A1 (en) | Bispecific antibodies against cd3 and cd20 for treating richter's syndrome | |
| HK40095625A (en) | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia | |
| HK40096389A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma | |
| HK40096702A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma | |
| HK40096765A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma | |
| HK40096947A (en) | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230405 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |